Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
16 November 2023 - 8:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(RULE 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of
the
Securities Exchange Act of 1934
(Amendment No. _)
Filed by the Registrant ☒ |
|
Filed by a Party other than the Registrant ☐ |
☐ |
Preliminary Proxy Statement |
☐ |
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
☐ |
Definitive Proxy Statement |
☒ |
Definitive Additional Materials |
☐ |
Soliciting Material Pursuant to §240.14a-12 |
DMK PHARMACEUTICALS
CORPORATION
(Name of Registrant as Specified In Its Charter)
Not Applicable
(Name of Person(s) Filing Proxy Statement, if other
than Registrant)
Payment of Filing Fee (Check the appropriate box): |
|
☒ |
No fee required. |
☐ |
Fee paid previously with preliminary materials |
☐ |
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): November
9, 2023
DMK PHARMACEUTICALS CORPORATION
(Exact Name of Registrant as Specified in Charter)
Delaware |
|
0-26372 |
|
82-0429727 |
(State or other jurisdiction of
incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
11622 El Camino Real, Suite 100
San Diego, CA |
|
92130 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area
code: (858) 997-2400
(Former name or Former Address, if Changed Since Last
Report.)
___________________________________________
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Exchange Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on
which registered |
Common Stock |
|
DMK |
|
NASDAQ
Capital Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
Emerging growth company ☐ |
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 |
Submission of Matters to a Vote of Security Holders. |
The disclosures under Item 8.01 below are incorporated
herein by reference, to the extent applicable.
DMK Pharmaceuticals Corporation (the “Company”)
convened its 2023 annual meeting of stockholders (the “Annual Meeting”) on November 9, 2023. The Company adjourned
the Annual Meeting to allow additional time for the Company to solicit additional proxies and votes to establish a quorum for the conduct
of business at the Annual Meeting and additional time for stockholders to vote on the proposals described in the Company’s notice
of meeting and definitive proxy statement filed with the Securities and Exchange Commission (“SEC”) on October 12, 2023 (the
“Proxy Statement”).
The
adjourned Annual Meeting will reconvene on November 30, 2023 at 9:00 a.m., Pacific Time. The adjourned Annual Meeting will
be a completely "virtual" meeting of stockholders, and stockholders will be able to listen and participate in the virtual meeting
as well as vote during the live webcast of the meeting by visiting www.virtualshareholdermeeting.com/DMK2023. To
participate in the virtual meeting, stockholders will need the control number found on their proxy cards or in the instructions that accompanied
their proxy materials. Only stockholders of record on the record date of October 6, 2023, are entitled to vote.
Important Information
In
connection with the solicitation of proxies for the Annual Meeting, the Company filed the Proxy Statement with the SEC. The
Company’s stockholders are strongly advised to read the definitive proxy materials, as supplemented, and any other relevant solicitation
materials filed by the Company with the SEC before making any voting decision because these documents contain important information.
The Company’s Proxy Statement and any other materials filed by the Company with the SEC can be obtained free of charge at the SEC’s
website at www.sec.gov.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
DMK PHARMACEUTICALS CORPORATION |
|
|
|
|
|
|
Dated: November 15, 2023 |
By: |
/s/ Seth A. Cohen |
|
Name: |
Seth A. Cohen |
|
Title: |
Chief Financial Officer |
DMK Pharmaceuticals (NASDAQ:DMK)
Historical Stock Chart
From May 2024 to Jun 2024
DMK Pharmaceuticals (NASDAQ:DMK)
Historical Stock Chart
From Jun 2023 to Jun 2024